Evidence map›Paper›PMID 36545210›Full record

ArticleMolecular and clinical oncology2023

Population‑based prostate‑specific antigen screening for prostate cancer may have an indirect effect on early detection through opportunistic testing in Kusatsu City, Shiga, Japan.

Susumu Kageyama, Yuki Okinaka, Koji Nishizawa, Toru Yoshida, Satoshi Ishitoya, Yasumasa Shichiri, Chul Jang Kim, Tsuyoshi Iwata, Ryusei Yokokawa, Yutaka Arai and 10 more

Open access · diamondAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Empirically derived dietary patterns and prostate cancer risk: a systematic review and meta-analysis of prospective cohorts.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Susumu KageyamaDepartment of Urology, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
Yuki OkinakaDepartment of Urology, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
Koji NishizawaDepartment of Urology, Shiga General Hospital, Moriyama, Shiga 524-8524, Japan.
Toru YoshidaDepartment of Urology, Shiga General Hospital, Moriyama, Shiga 524-8524, Japan.
Satoshi IshitoyaDepartment of Urology, Japanese Red Cross Otsu Hospital, Otsu, Shiga 520-8511, Japan.
Yasumasa ShichiriDepartment of Urology, Otsu City Hospital, Otsu, Shiga 520-0804, Japan.
Chul Jang KimDepartment of Urology, Kohka Public Hospital, Koka, Shiga 528-0074, Japan.
Tsuyoshi IwataDepartment of Urology, Omihachiman Community Medical Center, Omihachiman, Shiga 523-0082, Japan.
Ryusei YokokawaDepartment of Urology, Nagahama City Hospital, Nagahama, Shiga 526-8580, Japan.
Yutaka AraiDepartment of Urology, Kusatsu General Hospital, Kusatsu, Shiga 525-8585, Japan.
Zenkai NishikawaDepartment of Urology, Hino Memorial Hospital, Hino, Shiga 529-1642, Japan.
Hiroki SogaDepartment of Urology, Toyosato Hospital, Toyosato, Shiga 529-1168, Japan.
Hiroshi UshidaDepartment of Urology, JCHO Shiga Hospital, Otsu, Shiga 520-0846, Japan.
Yuji SakanoDepartment of Urology, National Hospital Organization Higashi-ohmi General Medical Center, Higashiomi, Shiga 527-8505, Japan.
Yoshio NayaDepartment of Urology, Nagahama City Kohoku Hospital, Nagahama, Shiga 529-0493, Japan.
Akinori WadaDepartment of Urology, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
Masayuki NagasawaDepartment of Urology, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
Tetsuya YoshidaDepartment of Urology, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
Mitsuhiro NaritaDepartment of Urology, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
Akihiro KawauchiDepartment of Urology, Shiga University of Medical Science, Otsu, Shiga 520-2192, Japan.
Shiga University of Medical Science · JPShiga Medical Center · JPNagahama City Hospital · JPNational Hospital Organization · JPOtsu Municipal Hospital · JPOtsu Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is the most common genitourinary cancer in men. Population-based serum prostate-specific antigen (PSA) testing is used to screen men for the early detection of asymptomatic prostate cancer. The present study compared the features of patients with prostate cancer in Kusatsu City, the only municipality in Shiga Prefecture of Japan to implement organized PSA screening, with those in other municipalities. The target population for organized PSA screening by mail invitation was men ≥50 years. Patients were pathologically diagnosed via prostate biopsy because of elevated serum PSA. This multicenter observational study was subsequently conducted in 14 hospitals. The following information was extracted from patient records: age, reason for PSA testing, initial PSA level, Gleason score, clinical stage, and place of residence. Risk classification was defined as low, intermediate, high, and advanced. Each patient was stratified according to their city/town. A total of 984 patients diagnosed with prostate cancer in Shiga in 2012 and 2017 were analyzed, of which 955 (97%) were opportunistically tested, with the remaining 29 (3%) assessed by organized screening. In Kusatsu, 93 patients were diagnosed, of whom 26 (28%) were detected by organized screening. By contrast, only three of 891 patients (0.3%) were detected by organized screening in other municipalities. Of patients in Kusatsu, cases identified by opportunistic testing had a higher initial PSA value (P=0.010) than those identified by organized screening. However, patients detected through opportunistic testing in Kusatsu City were younger (P=0.034), had a lower PSA value (P=0.001), and improved risk classification (P<0.001) than those in other municipalities. It was concluded that more patients were diagnosed with early-stage cancer by organized PSA screening. Furthermore, population-based PSA screening in Kusatsu City may have indirectly affected early detection, even by opportunistic testing.

Indexed as

diagnosisopportunistic testingpopulation-based screeningprostate cancerprostate-specific antigen

Identifiers

PMID36545210
PMCPMC9756018
OpenAlexW4309789975

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.